Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics Secures $98 Million in New Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$882.0 million","upfrontCash":"$42.0 million","newsHeadline":"Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Stem Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Pritzker Neuropsychiatric Disorders Research Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Will Use Modality.AI in its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Verge Genomics

    Menu

    Verge Genomics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Verge Genomics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

              Details:

              The collaboration aims to co-develop VRG50635, Verge’s potent, orally bioavailable PIKfyve inhibitor, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS), in Europe, Central and South America, Southeast Asia and Japan.

              Lead Product(s): VRG50635

              Therapeutic Area: Neurology Product Name: VRG50635

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ferrer Internacional

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635

              Details:

              VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS. It is under phase 1 clinical development for the treatment of amyotrophic lateral sclerosis.

              Lead Product(s): VRG50635

              Therapeutic Area: Neurology Product Name: VRG50635

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Will Use Modality.AI in its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635

              Details:

              VRG50635 is a PIKfyve Inhibitor, small molecule drug therapy, administered orally, currently being investigated for amyotrophic lateral sclerosis treatment.

              Lead Product(s): VRG50635

              Therapeutic Area: Neurology Product Name: VRG50635

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration

              Details:

              Under the collaboration, Verge will use CONVERGE®, its all-in-human, AI-powered platform, to identify novel therapeutic targets by using data generated from postmortem brain tissue provided by schizophrenia patients and healthy donors.

              Lead Product(s): Undisclosed

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Pritzker Neuropsychiatric Disorders Research Consortium

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson’s Disease

              Details:

              The collaboration aims to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD), by leveraging Stem Pharm's cutting-edge human-first technologies and expertise.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Stem Pharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases

              Details:

              The collaboration aims to identify novel drug targets for rare neurodegenerative and neuromuscular diseases by leveraging CONVERGE, a full-stack platform that combines highly predictive human tissue datasets with machine learning to find new targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

              Deal Size: $882.0 million Upfront Cash: $42.0 million

              Deal Type: Collaboration September 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

              Details:

              VRG50635 is a potential best-in-class small molecule inhibitor of PIKfyve for treatment of ALS. PIKfyve is a new therapeutic target for ALS discovered using CONVERGE™, the company’s all-in-human, AI-powered platform.

              Lead Product(s): VRG50635

              Therapeutic Area: Neurology Product Name: VRG50635

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis

              Details:

              VRG50635 is a potent PIKfyve inhibitor that restores endolysosomal function in ALS patient neurons and has shown efficacy in multiple preclinical studies in ALS-relevant models of motor neuron degeneration.

              Lead Product(s): VRG50635

              Therapeutic Area: Neurology Product Name: VRG50635

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Secures $98 Million in New Financing

              Details:

              Funding from the Series B will be used to exponentially grow the number of preclinical and clinical programs in Verge’s pipeline and advance its lead programs through clinical testing.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: BlackRock

              Deal Size: $98.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing December 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verge Genomics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral

              Details:

              In an in vivo study of SARS-CoV-2 infected hamsters, following four-day treatment, animals treated with VRG101 at 50 mg/kg showed significant improvement in lung pathology compared to vehicle controls.

              Lead Product(s): VRG101

              Therapeutic Area: Infections and Infectious Diseases Product Name: VRG101

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY